Xi Tan1, Fabian Camacho2, Vincent D Marshall3, Joseph Donohoe4, Roger T Anderson2, Rajesh Balkrishnan5. 1. West Virginia University, School of Pharmacy, Robert C. Byrd Health Sciences Center-North, P.O. Box 9510, Morgantown, WV 26505, USA. 2. University of Virginia, School of Medicine, P.O. Box 800717, Charlottesville, VA 22908, USA. 3. University of Michigan, College of Pharmacy, 428 Church Street, Ann Arbor, MI 48105, USA. 4. Mountain-Pacific Quality Health, 3404 Cooney Drive, Helena, MT 59602, USA. 5. University of Virginia, School of Medicine, P.O. Box 800717, Charlottesville, VA 22908, USA. Electronic address: rb9ap@eservices.virginia.edu.
Abstract
BACKGROUND: Appalachia is a largely rural, mountainous, poor and underserved region of the United States. Adherence to adjuvant endocrine therapy among Appalachian women with breast cancer is suboptimal. OBJECTIVES: To explore small-area geographic variations and clustering patterns of breast cancer patient adherence to adjuvant endocrine therapy and associated factors in Appalachia. METHODS: In this retrospective study, we analyzed Medicare claims data linked with cancer registries from four Appalachian states (PA, OH, KY, and NC) in 2006-2008. We included adult women who were diagnosed with stage I-III, hormone-receptor positive, primary breast cancer and who newly started adjuvant endocrine therapy after the primary treatment for breast cancer. Hot spot analysis was conducted to explore geographic variations in adjuvant endocrine therapy adherence. Geographically weighted logistic regression (GWLR) was used to examine whether the impacts of factors associated with adherence varied across the region. RESULTS: Breast cancer patients living in PA and OH showed higher adherence to adjuvant endocrine therapy than those living in KY and NC. We identified clusters of high adherence in most of PA but poor adherence in Erie County, PA and in Buncombe, Transylvania, Henderson, and Polk Counties, NC. Adherence to adjuvant endocrine therapy was significantly associated with the Health Professional Shortage Area designation, catastrophic coverage, dual-eligibility status of Medicaid and Medicare, adjuvant endocrine therapy drug class, and side effects. And among these factors, the impacts of dual-eligibility status and the use of pain medications to treat side effects on adherence were more pronounced in KY and NC than in PA. CONCLUSIONS: There were significant geographic disparities in adherence to adjuvant endocrine therapy in the Appalachian counties in PA, OH, KY, and NC. This study explored these geographic areas with poor adherence as well as geographically varying effects of predictors on adherence; our results may provide more localized information that may be used to improve adjuvant therapy use and breast cancer care in these high-risk and underserved areas.
BACKGROUND: Appalachia is a largely rural, mountainous, poor and underserved region of the United States. Adherence to adjuvant endocrine therapy among Appalachian women with breast cancer is suboptimal. OBJECTIVES: To explore small-area geographic variations and clustering patterns of breast cancerpatient adherence to adjuvant endocrine therapy and associated factors in Appalachia. METHODS: In this retrospective study, we analyzed Medicare claims data linked with cancer registries from four Appalachian states (PA, OH, KY, and NC) in 2006-2008. We included adult women who were diagnosed with stage I-III, hormone-receptor positive, primary breast cancer and who newly started adjuvant endocrine therapy after the primary treatment for breast cancer. Hot spot analysis was conducted to explore geographic variations in adjuvant endocrine therapy adherence. Geographically weighted logistic regression (GWLR) was used to examine whether the impacts of factors associated with adherence varied across the region. RESULTS:Breast cancerpatients living in PA and OH showed higher adherence to adjuvant endocrine therapy than those living in KY and NC. We identified clusters of high adherence in most of PA but poor adherence in Erie County, PA and in Buncombe, Transylvania, Henderson, and Polk Counties, NC. Adherence to adjuvant endocrine therapy was significantly associated with the Health Professional Shortage Area designation, catastrophic coverage, dual-eligibility status of Medicaid and Medicare, adjuvant endocrine therapy drug class, and side effects. And among these factors, the impacts of dual-eligibility status and the use of pain medications to treat side effects on adherence were more pronounced in KY and NC than in PA. CONCLUSIONS: There were significant geographic disparities in adherence to adjuvant endocrine therapy in the Appalachian counties in PA, OH, KY, and NC. This study explored these geographic areas with poor adherence as well as geographically varying effects of predictors on adherence; our results may provide more localized information that may be used to improve adjuvant therapy use and breast cancer care in these high-risk and underserved areas.
Authors: Lorena Rocha Ayres; André de Oliveira Baldoni; Anna Paula de Sá Borges; Leonardo Régis Leira Pereira Journal: Int J Clin Pharm Date: 2013-08-11
Authors: Yihang Liu; Jennifer L Malin; Allison L Diamant; Amardeep Thind; Rose C Maly Journal: Breast Cancer Res Treat Date: 2012-12-23 Impact factor: 4.872
Authors: John F Forbes; Jack Cuzick; Aman Buzdar; Anthony Howell; Jeffrey S Tobias; Michael Baum Journal: Lancet Oncol Date: 2008-01 Impact factor: 41.316
Authors: Vanessa B Sheppard; Arnethea L Sutton; Alejandra Hurtado-de-Mendoza; Jun He; Bassam Dahman; Megan C Edmonds; Mary Helen Hackney; Mahlet G Tadesse Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-01-29 Impact factor: 4.254
Authors: Fabian T Camacho; Xi Tan; Héctor E Alcalá; Surbhi Shah; Roger T Anderson; Rajesh Balkrishnan Journal: Medicine (Baltimore) Date: 2017-06 Impact factor: 1.817